Sanofi aims for Nexviazyme approval in younger Pompe disease patients

Data ReadoutpositiveNexviazymePositive

AI Analysis

Summary

Sanofi's Nexviazyme met all primary and secondary endpoints in the Baby-COMET trial for younger Pompe disease patients, supporting potential label expansion. The positive results advance the drug's application in pediatric populations.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Met all primary and secondary endpoints in Baby-COMET trial

Importance:6/10

Sentiment:

0.75

Pompe diseaselabel expansionpediatricenzyme replacement therapy

Related Companies

$SNY

Read the original article

Published by Pharmaceutical Technology on July 1, 2026 1:57 PM

Read Original